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Regulation of mRNA export by the PI3 
kinase/AKT signal transduction pathway
Alexandre Jose Christino Quaresma, Rachel Sievert, and Jeffrey A. Nickerson
Department of Cell and Developmental Biology, University of Massachusetts Medical School, Worcester, MA 01655
ABSTRACT UAP56, ALY/REF, and NXF1 are mRNA export factors that sequentially bind at 
the 5′ end of a nuclear mRNA but are also reported to associate with the exon junction com-
plex (EJC). To screen for signal transduction pathways regulating mRNA export complex as-
sembly, we used fluorescence recovery after photobleaching to measure the binding of 
mRNA export and EJC core proteins in nuclear complexes. The fraction of UAP56, ALY/REF, 
and NXF1 tightly bound in complexes was reduced by drug inhibition of the phosphati-
dylinositide 3-kinase (PI3 kinase)/AKT pathway, as was the tightly bound fraction of the core 
EJC proteins eIF4A3, MAGOH, and Y14. Inhibition of the mTOR mTORC1 pathway decreased 
the tight binding of MAGOH. Inhibition of the PI3 kinase/AKT pathway increased the export 
of poly(A) RNA and of a subset of candidate mRNAs. A similar effect of PI3 kinase/AKT inhibi-
tion was observed for mRNAs from both intron-containing and intronless histone genes. 
However, the nuclear export of mRNAs coding for proteins targeted to the endoplasmic re-
ticulum or to mitochondria was not affected by the PI3 kinase/AKT pathway. These results 
show that the active PI3 kinase/AKT pathway can regulate mRNA export and promote the 
nuclear retention of some mRNAs.
INTRODUCTION
The export of RNA molecules from the nucleus to the cytoplasm is 
a critical step in cellular maintenance. The export mechanisms for 
different classes of RNA share a common approach; RNAs are pack-
aged in messenger ribonucleoprotein (mRNP) complexes that bind 
export receptors that subsequently dock the complex at nuclear 
pores for translocation to the cytoplasm (Rodriguez et al., 2004; 
Stewart, 2007). The export receptor for most mRNAs is NXF1. In this 
export mechanism, the ATP-dependent RNA helicase UAP56 is 
deposited on mRNA during splicing. UAP56 recruits the adapter 
protein ALY/REF (Luo et al., 2001), which in turn binds the NXF1-p15 
heterodimer that is required for most mRNA export in species from 
yeast to humans (Segref et al., 1997; Grüter et al., 1998; Herold 
et al., 2001).
In one model, this complex of UAP56, ALY/REF, and NXF1-p15 
associates with a spliced mRNA at the capped 5′ end of the mRNA 
(Cheng et al., 2006). UAP56 and ALY/REF are members of the tran-
scription/export (TREX) complex located at the 5′ end (Bensaude, 
2011; Nechaev and Adelman, 2011). NXF1 recruited to the complex 
may subsequently bind at nuclear pores (Forler et al., 2004), and 
also to transportin-2 (Shamsher et al., 2002), for export of the mRNP 
complex from the nucleus.
A second complex, the exon junction complex (EJC), forms on the 
mRNA at sites 24 nucleotides upstream from exon–exon junctions 
(Singh et al., 2012) and could play a role in export to the cytoplasm. 
The crystal structure of the core EJC with eIF4A3, MLN51, MAGOH, 
and Y14 bound to polyU has been solved (Andersen et al., 2006; 
Bono et al., 2006). UAP56, ALY/REF, and NXF1 are all reported to be 
members of an extended EJC (Kataoka et al., 2000; Le Hir et al., 
2000). In vitro, at least three EJC proteins—UAP56, Y14, and MA-
GOH—bind to the export receptor NXF1–p15 heterodimer (Kataoka 
et al., 2001). Proteins interacting with the EJC also mediate the trans-
lational repression and nonsense-mediated decay of mRNAs con-
taining premature stop codons (Singh et al., 2007; Isken et al., 2008). 
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The PI pathway is a central regulator of 
cell metabolism, gene expression, and 
development (Yuan and Cantley, 2008; 
Chalhoub and Baker, 2009; Skwarek 
and Boulianne, 2009). PI(4,5)P2 is the key 
pathway intermediate; it can be further 
phosphorylated by phosphatidylinositol 
3-kinase (PI3 kinase), generating PI(3,4,5)
P3, which is a potent activator of several 
downstream effectors, including AKT 
(Altomare and Testa, 2005). Surprisingly, 
PI(4,5)P2 is present in the nucleus at RNA-
splicing speckled domains, which are en-
riched in mRNA-splicing and export factors 
(Boronenkov et al., 1998; Osborne et al., 
2001; Stallings et al., 2005; Bunce et al., 
2006). The nucleus of a typical cell has 
20–40 RNA-splicing speckled domains 
around which transcription, RNA splicing, 
and RNA export from the nucleus are orga-
nized. A majority of, but not all, pre-mRNA 
transcripts are spliced at or near these 
domains (Smith et al., 1999), and some 
mRNAs move into the interior of these 
domains and bind before release to the 
cytoplasm (Shopland et al., 2002).
In this study we used fluorescence recov-
ery after photobleaching (FRAP) to screen 
proteins present in mRNA export complexes 
for changes in binding after inhibition of the 
PI3K/AKT or mTOR signal transduction 
pathways. PI3 kinase and AKT did regulate 
the binding affinity of the essential mRNA 
export proteins UAP56 and NXF1 in com-
plexes formed at RNA-splicing speckled do-
mains and at sites in the nucleoplasm. The 
assembly of the core EJC proteins eIF4A3, 
MAGOH, and Y14 into complexes at speck-
led domains was also altered by inhibition of 
PI3 kinase or AKT. MAGOH binding was 
strongly reduced by the inhibition of mTOR. The activated PI3K/
AKT pathway caused increased retention of poly(A) RNA and spe-
cific mRNAs in the nucleus, consistent with this signal transduction 
pathway regulating the export of mRNA.
RESULTS
The binding of mRNA export proteins in live cells 
is regulated by PI3 kinase and AKT
FRAP measures the relative kinetics and affinities of fluorescent pro-
tein binding in complexes that are immobile over the time course of 
the experiment (Wagner et al., 2004; Lele et al., 2006; Lele and 
Ingber, 2006; Kota et al., 2008; Nickerson, 2009). To identify mRNA 
export factors whose assembly into export complexes is regulated 
by the PI signal transduction pathway, we screened enhanced green 
fluorescent protein (EGFP)-fusion proteins of known mRNA export 
factors for altered photobleach recovery kinetics after drug inhibi-
tion of the PI pathway in live HeLa cells. EGFP-UAP56 was most 
concentrated at RNA-splicing speckled domains (Supplemental 
Figure S1 and Supplemental Movie S1), consistent with previous re-
sults (Kota et al., 2008). After photobleaching, EGFP-UAP56 fluores-
cence recovered at speckled domains with a half-time (t1/2) of 15.6 s 
(Figure 1 and Table 1). An immobile fraction of 27.7% was measured, 
RNA export proteins joining the EJC in the nucleus stimulate transla-
tion of the mRNA in the cytoplasm (Wiegand et al., 2003; Nott et al., 
2004), an effect mediated by the mTOR pathway (Ma et al., 2008).
Some mRNAs leave the nucleus by alternative mechanisms. 
For example, a family of proliferation-related mRNAs sharing a 
50-nucleotide sequence element in their 3′ untranslated region are 
exported by a mechanism requiring the eukaryotic translation initia-
tion factor eIF4E and the export receptor CRM1 but not NXF1–p15 
(Culjkovic et al., 2006). Incorporation of the signal sequence coding 
region (SSCR) in an mRNA can facilitate efficient nuclear export 
even in the absence of an intron or 5′ cap structure. SSCR-mediated 
nuclear export requires NXF1 but not UAP56 or the similar URH49 
(Palazzo et al., 2007).
The regulation of mRNA export is inadequately understood. 
One report identified threonine-219 (T219) on human ALY/REF 
as an AKT phosphorylation site (Okada et al., 2008). Point mutation 
of this site has a dominant-negative effect on mRNA export 
and inhibits cell proliferation. ALY/REF also binds in vitro to phos-
phatidylinositol-(3,4,5)-tris-phosphate (PI(3,4,5)P3) and phosphati-
dylinositol-(4,5)-bis-phosphate (PI(4,5)P2). These results linked a 
TREX complex protein to the phosphatidylinositol (PI) signal trans-
duction pathway.
FIGURE 1: The binding of mRNA export complex proteins, as measured by FRAP, is regulated 
by PI3 kinase, AKT, and mTOR. HeLa cells were transfected with EGFP-fusion proteins for 
UAP56, ALY/REF, and NXF1. After 48 h, cells were treated with 20 μM of the PI3 kinase inhibitor 
LY294002 (green circles) for 2 h, 5 μM of AKT inhibitor VIII (blue triangles) for 3.5 h, and 100 nM 
of the mTOR inhibitor rapamycin (red squares) for 5 h. Multiple cells were examined by FRAP 
over a 2-h interval in all treatment groups. The times between drug addition and photobleaching 
are reported as a mean. Black squares, untreated cells. Normalized fluorescence recovery curves 
are presented for EGFP-UAP56, EGFP-TAP/NXF1, and EGFP-ALY/REF. Also shown is EGFP-
UAP56 K95N, a point mutant that cannot bind ATP. Each colored arrow marks the t1/2 of 
recovery for the curve of the same color. Statistical analysis of the differences between averaged 
FRAP curves was by paired one-tailed t test: untreated EGFP-UAP56 vs. LY294002 (p = 0.0083), 
AKT (p < 0.0001), rapamycin (p = 0.2799); untreated EGFP-ALY/REF vs. LY294002 (p < 0.0001), 
AKT (p < 0.0001), rapamycin (p < 0.0001); untreated EGFP-NXF1 vs. LY294002 (p = 0.0002), AKT 
(p = 0.0004), rapamycin (p = 0.4102). Means are plotted with error bars for standard errors. n, 
number of cells in each treatment group.
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with Akt inhibitor VIII increased the t1/2 to 7.2 and 8.8 s, respectively 
(Table 1). Moreover these two treatments significantly reduced the 
tightly bound fraction from the 21.4% in control cells to 6.9 and 
9.2%, respectively. After inhibition of mTOR with rapamycin the re-
covery rate was increased to 6.9 s and the immobile fraction in-
creased to 23.7% (Figure 1 and Table 1).
UAP56 is an ATP-dependent RNA helicase. We showed that a 
point mutant of UAP56 that cannot bind ATP (UAP56 K95N) has a 
reduced association with complexes at RNA-splicing speckled do-
mains and has a dominant-negative effect on the export of a splic-
ing reporter mRNA (Kota et al., 2008). A similar point mutant in 
UAP56 of Saccharomyces cerevisiae inhibited its function (Zhang 
and Green, 2001). In control experiments, EGFP-UAP56K95N was 
less concentrated at speckled domains and, after a photobleach, 
recovered with t1/2 = 2.6 s and a very small immobile fraction 
(5.8%), both consistent with low-affinity binding. For this mutant, 
there was no significant change in the photobleach recovery ki-
netics or in the immobile fraction caused by drug treatments 
(Figure 1 and Table 1).
We verified the effectiveness of the drug treatments used in 
these FRAP experiments. Cells were treated for 4 h with LY294002 
(20 μM), AKT VIII (5 μM), or rapamycin (100 nM). As shown in the 
Western blot of Supplemental Figure S2, AKT phosphorylation at 
threonine 308 was inhibited after treatment with LY294002 or AKT 
VIII, so both drug treatments eliminated AKT activation in the PI 
pathway. Rapamycin eliminated the activating phosphorylation of 
mTOR at serine 2448 (Supplemental Figure S2).
The region-of-interest photobleaching results reported in 
Figure 1 averaged together recovery for the pool of EGFP-UAP56 
at speckled domains and at adjacent nucleoplasmic sites. When we 
compared the fluorescence recovery of EGFP-UAP56 in the nucleo-
plasm with the recovery at speckled domains, we found that the 
nucleoplasmic and speckled domain fluorescence had tightly 
bound immobile fractions of 26.5 and 40.5%, respectively. PI3 ki-
nase inhibition decreased the immobile fraction markedly to 7.6% 
for nucleoplasmic EGFP-UAP56 and 2.8% for UAP56 in speckled 
domains (Figure 2). UAP56 binding in both compartments is simi-
larly affected by inhibition of the PI pathway at PI3 kinase or AKT.
The binding of EJC core proteins is also affected by the PI3 
kinase/AKT pathway
UAP56, ALY/REF, and NXF1 are recruited to the 5′ end of an mRNA 
for export (Cheng et al., 2006) but are also reported to associate 
with the EJC (Le Hir et al., 2000, 2001). Structural studies of the EJC 
show it to have a stable core consisting of the proteins eIF4A3, 
MLN51, and the Y14/MAGOH heterodimer (Andersen et al., 2006; 
Bono et al., 2006). We used FRAP after PI or mTOR pathway 
which represents the tightly bound fraction that did not exchange 
during the time course of the experiment. After inhibition of PI3 ki-
nase with LY294002 for 2–3 h, the recovery half-time increased to 
21.2 s (Figure 1 and Table 1), and the tightly bound immobile frac-
tion was markedly decreased from 27.7 to 17.1% (Figure 1 and Table 
1). This immobile fraction represents the fraction of UAP56 bound in 
more stable complexes. The immobile fraction of EGFP-UAP56 was 
similarly reduced from 27.7 to 8.5% by inhibition of AKT with 5 μM 
Akt inhibitor VIII for 3–4 h (Vlahos et al., 1994; Barnett et al., 2005).
AKT is activated downstream of PI3 kinase by phosphorylation at 
threonine 308 (Alessi et al., 1996), but mTOR signaling through 
mTORC2 can also influence AKT activity (Nave et al., 1999) by phos-
phorylation of AKT at serine 473 (Sarbassov et al., 2005; Jacinto 
et al., 2006). Akt inhibitor VIII is an allosteric inhibitor of AKT 1 
(IC50 = 58 nM), AKT2 (IC50 = 210 nM), and AKT3 (IC50 = 2119 nM; 
Lindsley et al., 2005) that inhibits the activating phosphorylations of 
both T308 and S473 (AKT1 numbering; Calleja et al., 2009). This 
gives this inhibitor greater specificity for AKT than other inhibitors 
that target the ATP-binding sites of AKT, sites that have conserved 
features with other ATP-binding proteins. The crystal structure of Akt 
inhibitor VIII inhibitor bound to AKT1 was solved (Wu et al., 2010). 
This compound and its derivatives are candidate agents for cancer 
therapy (Liu et al., 2009).
Rapamycin, although an mTOR inhibitor, inhibits only TORC1 
complex signaling and does not affect the activity of AKT during the 
time periods of our experiment (Sarbassov et al., 2006). Inhibition of 
mTOR with 100 nM rapamycin for 4 h did not significantly change 
the photobleach recovery kinetics or the tightly bound immobile 
fraction (27.8%) compared with control cells without mTOR inhibi-
tion (Figure 1 and Table 1).
UAP56 recruits ALY/REF to mRNA export complexes. EGFP-ALY/
REF is also concentrated at the nuclear speckled domains (Supple-
mental Figure S1 and Supplemental Movie S2). There was little effect 
of PI3 kinase inhibition on the t1/2 for photobleach recovery of EGFP-
ALY/REF (Figure 1 and Table 1). However, inhibition of PI3 kinase, 
AKT, or mTOR TORC1 decreased the immobile fraction. For exam-
ple, this tightly bound fraction was reduced from 15.3% in control 
cells to <5% after AKT inhibition. This in vivo result is consistent with 
previous evidence of ALY/REF phosphorylation by AKT (Okada et al., 
2008). Our data suggest that AKT phosphorylation causes a fraction 
of ALY/REF to bind more tightly in complexes at speckled domains.
In the export mechanism proposed for mRNA, UAP56 and ALY/
REF then recruit the export receptor NXF1 (Grüter et al., 1998; 
Herold et al., 2001; Luo et al., 2001). EGFP-NXF1 (Supplemental 
Figure 1 and Supplemental Movie S3) recovered after photobleach-
ing at speckled domains with t1/2 = 4.4 s and an immobile fraction 
of 21.4%. Inhibition of PI3 kinase with LY294002 or inhibition of AKT 
EGFP-UAP56 EGFP-NFX1 EGFP-ALY/REF EGFP-UAP56 K95N
Untreated Half-time (s) 15.6 4.4 6.8 2.6
Immobile fraction (%) 27.7 ± 1.2 21.4 ± 3.6 15.3 ± 2.0 5.8 ± 1.1
LY294002 Half-time (s) 21.2 7.2 5.5 2.7
Immobile fraction (%) 17.1 ± 1.9 6.9 ± 1.6 6.9 ± 1.4 6.0 ± 0.7
AKT I VIII Half-time (s) 15.7 8.8 7.4 2.8
Immobile fraction (%) 8.5 ± 0.9 9.2 ± 1.6 4.12 ± 1.8 3.5 ± 0.2
Rapamycin Half-time (s) 14.8 6.9 6.6 2
Immobile fraction (%) 27.8 ± 1.3 23.7 ± 3.1 10.4 ± 2.2 6.6 ± 0.7
TABLE 1: FRAP measurements for mRNA export proteins.
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through AKT. We propose that both path-
ways are regulators of mRNA export protein 
binding at speckled domains.
Because MAGOH interacts with Y14, 
forming a heterodimer, and Y14 is a putative 
mRNA export factor (Kataoka et al., 2001), 
we measured the binding of EGFP-Y14 at 
speckled domains by FRAP (Supplemental 
Figure S3 and Supplemental Movie S6). 
EGFP-Y14 recovered very rapidly at speck-
led domains (t1/2 = 4.5 s) with a high immo-
bile fraction of 56%. Drug treatments did 
not significantly change the kinetics of re-
covery for the rapidly exchanging fraction. 
However, after inhibition of PI3 kinase the 
immobile fraction of EGFP-Y14 was de-
creased to 43.8% (Figure 3 and Table 2). In-
hibition of AKT had greater effect, reducing 
the tightly bound fraction to 37.3%. Inhibi-
tion of mTOR had no significant effect.
Like UAP56, eIF4A3 is an ATP-depen-
dent RNA helicase of the DExD/H family 
(Linder, 2008). A point mutant of eIF4A3 
that is unable to bind to ATP (Shibuya et al., 
2006) was cloned. EGFP-eIF4A3 with this 
K88N point mutation was less concentrated 
at speckled domains than was the wild-type 
eI4A3 but was, instead, more widely distrib-
uted in the nucleoplasm, similar to the distri-
bution of the UAP56 K95N point mutant, 
which cannot bind ATP (Kota et al., 2008). 
EGFP-eIF4A3K88N was not, however, ex-
cluded from speckled domains, where it re-
covered after a photobleach with t1/2 = 3.4 s 
and an immobile fraction of 16.8%. This de-
creased binding compared with the wild-
type protein (5.3 s, 27.2%) is consistent with 
decreased speckled domain localization. The tightly bound immo-
bile fraction of EGFP-eIF4A3 K88N significantly decreased only after 
PI3 kinase inhibition with LY294002 to 11.4%. The half-time of pho-
tobleach recovery was decreased after PI3 kinase, AKT, or mTOR 
inhibition from 3.4 s to 2.4, 1.4, and 1.8 s, respectively (Figure 3). 
This mutant eIF4A3, which can still be incorporated in the EJC core 
complex (Shibuya et al., 2006), retained the ability to be affected by 
both PI pathway and mTOR pathway signaling.
Inhibition of the PI3 kinase/AKT pathway increases 
the export of poly(A) RNA
Because the inhibition of PI3K, AKT, or mTOR affected the binding 
of mRNA export–related proteins in live cells, we reasoned that 
those changes might have consequences on the export of some 
mRNAs from the nucleus to cytoplasm. We performed a standard 
mRNA export assay according to Okada et al. (2008) 
and Wickramasinghe et al. (2010), quantifying nuclear or cytoplas-
mic poly(A) RNA with biotinylated oligo(dT) and Alexa 488–strepta-
vidin (Figure 4). Inhibition of PI3 kinase with LY294002 or inhibition 
of AKT with AKT I VIII caused a significant decrease in nuclear 
poly(A) RNA and a significant increase in cytoplasmic poly(A) RNA 
without changing the total signal per cell. Using both inhibitors 
simultaneously caused a larger effect, increasing our confidence 
that the PI3 kinase/AKT branch of this complicated pathway is af-
fecting mRNA export (Figure 4).
inhibition to explore the regulation of EJC core protein binding at 
RNA-splicing speckled domains.
As shown in Figure 3, fluorescence of EGFP-eIF4A3 (Supplemen-
tal Figure S3 and Supplemental Movie S4) recovered at photo-
bleached speckled domains with t1/2 = 6.2 s and a higher immobile 
fraction than UAP56 (55.4%). EGFP-eIF4A3 showed a significant de-
crease in the t1/2 of recovery after PI3 kinase, AKT, and mTOR inhibi-
tion (Table 2). In addition, the immobile fraction also decreased 
markedly to 36.4 and 33.7%, respectively, after PI3 kinase or AKT 
inhibition (Figure 3 and Table 2). eIF4A3 and MAGOH are core pro-
teins of the EJC. EGFP-MAGOH, which also localized to speckled 
domains (Supplemental Figure S3 and Supplemental Movie 5), re-
covered with t1/2 = 10.2 s and showed the highest immobile, or 
tightly bound, fraction (72%) of any protein in this study. Inhibition of 
PI3 kinase, AKT, or rapamycin did not significantly affect the initial 
recovery rate (Figure 3 and Table 2). However, the immobile fraction 
was greatly decreased after all three drug treatments, with inhibition 
of mTOR having the largest effect and reducing the immobile frac-
tion of MAGOH to 42.2%. Inhibition of PI3 kinase and AKT decreased 
the tightly bound fraction to 47.7 and 51.2%, respectively (Table 2). 
These results suggest that the mTOR pathway can regulate the bind-
ing of EJC core proteins in complexes at RNA-splicing speckled do-
mains. Further, the effect of mTOR inhibition on the tightly bound, 
immobile fraction of MAGOH was larger than the effect of AKT or 
PI3 kinase inhibition, suggesting that mTOR did not act entirely 
FIGURE 2: EGFP-UAP56 is more tightly bound at nuclear speckled domains than at sites in the 
nucleoplasm. HeLa cells were transfected with EGFP-UAP56 wild type, and then, after 48 h, cells 
were treated for 3–5 h with 25 μM LY294002. Normalized fluorescence recovery curves over 
time were calculated for regions of interest, including either individual speckles or regions of the 
nucleoplasm devoid of speckles. n, number of cells for each graph. Means were plotted, with 
error bars showing the standard errors for each collected time point.
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assessing nuclear export of mRNA (Strasser 
et al., 2002; Okada et al., 2008; Wickramas-
inghe et al., 2010). There are limitations to 
this approach; the results present an aver-
age nuclear-to-cytoplasmic ratio for a very 
heterogeneous population that includes 
many nuclear poly(A) RNA species that are 
noncoding and not exported (Brown et al., 
1992; Rinn et al., 2007; Amaral et al., 2011). 
For mRNAs the export of different species 
may be regulated differently and, therefore, 
differentially affected by the experimental 
manipulation.
For these reasons, we quantified changes 
in the nuclear-to-cytoplasmic ratio of spe-
cific mRNAs by quantitative real-time (qRT)-
PCR assay. In initial experiments, drug inhi-
bition of PI3 kinase and AKT treatments 
changed the nuclear-to-cytoplasmic ratio of 
several housekeeping gene mRNAs that are 
commonly used for normalization. Normal-
ization by cell number was an improvement, 
but there were experiment-to-experiment 
variations that we attributed to the varying 
yield in RNA isolation from nuclear and cyto-
plasmic fractions.
To overcome this problem, we designed 
an assay with improved quantification for 
measuring the nuclear and cytoplasmic frac-
tions of individual mRNA species by normal-
ization to a synthetic internal standard RNA 
added to the nucleus and to the cytoplasm 
in exactly the same amount before RNA iso-
lation. In vitro–transcribed miniUAA1 mRNA, 
an RNA not present in human cells, was 
used as the synthetic internal standard 
(Wong and Medrano, 2005; Amrani et al., 
2008). Normalization to this internal stan-
dard corrected for any nuclear-to-cytoplasmic or sample-to-sample 
variation in protocol steps, including TRIzol mRNA isolation, RNA 
precipitation, DNase I digestion, and reverse transcription to gener-
ate cDNAs. The use of an internal standard also allowed the calcula-
tion of real rather than relative nuclear-to-cytoplasmic ratios.
RNA from whole cells, as well as from the separated cytoplasmic 
and nuclear fractions, each spiked with a constant and known mass 
of the internal standard, was extracted and isolated before qRT-PCR 
to quantify individual species. The quality of our separation of nu-
cleus and cytoplasm was measured by RT-PCR. The nuclear 
The drug treatments did not change the poly(A) distribution 
within the nucleus, where it was most concentrated in RNA-splicing 
speckled domains. In the cytoplasm, however, AKT inhibition caused 
a decreased perinuclear localization of poly(A). This change was not 
seen after PI3 kinase or mTOR inhibition.
Inhibition of AKT increases the export of specific 
endogenous mRNAs
Measurement of nuclear and cytoplasmic poly(A) levels by fluores-
cence in situ hybridization (FISH) has been a standard assay for 
FIGURE 3: The binding of EJC core proteins, as measured by FRAP, is regulated by PI3 kinase, 
AKT, and mTOR. HeLa cells were transfected with EGFP-fusion proteins. After 48 h, cells were 
treated with 20 μM PI3 kinase inhibitor LY294002 (green circles) for 2.5 h, 5 μM AKT inhibitor VIII 
(blue triangles) for 3.5 h, or 100 nM of the mTOR inhibitor rapamycin (red squares) for 4.5 h. 
Black squares, untreated cells. Normalized fluorescence recovery curves are presented for the 
EJC fusion proteins EGFP-eIF4A3, EGFP-MAGOH, and EGFP-Y14. Also shown is EGFP-eIF4A3 
K88N, a point mutant that cannot bind ATP. Each colored arrow marks the t1/2 of recovery for 
the curve of the same color. Statistical analysis of the differences between averaged FRAP 
curves was by paired one-tailed t test: untreated EGFP-eIF4A3 vs. LY294002 (p = 0.0002), AKT 
(p = 0.0002), rapa mycin (p = 0.0002); untreated EGFP-MAGOH vs. LY294002 (p = 0.0001), AKT 
(p = 0.0001), rapamycin (p = 0.0001); untreated EGFP-Y14 vs. LY294002 (p = 0.0001), AKT (p = 
0.0001), rapamycin (p = 0.0527). Means are plotted with standard errors for n cells in each 
treatment group.
EGFP-eIF4A3 EGFP-MAGOH EGFP-Y14 EGFP-eIF4A3 K88N
Untreated Recovery half-time (s) 6.2 10.2 4.5 3.4
Immobile fraction (%) 55.4 ± 3.0 72.0 ± 1.5 56.0 ± 2.0 16.8 ± 0.8
LY294002 Recovery half-time (s) 3.4 12.1 5.2 2.4
Immobile fraction (%) 36.4 ± 2.5 47.7 ± 4.2 43.8 ± 3.6 11.0 ± 0.7
AKT I VIII Recovery half-time (s) 3.6 12.9 4.3 1.5
Immobile fraction (%) 33.7 ± 2.9 51.2 ± 3.4 37.3 ± 2.2 17.0 ± 0.6
Rapamycin Recovery half-time (s) 4.1 10.9 5.6 1.8
Immobile fraction (%) 51.46 ± 2.5 42.2 ± 4.0 61.4 ± 2.4 16.1 ± 0.6
TABLE 2: FRAP measurements for proteins of the EJC core complex.
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Intronless mRNAs are exported efficiently 
by mechanisms using UAP56, ALY/REF, and 
NXF1 (Huang et al., 1999, 2003; Huang and 
Steitz, 2001; Herold et al., 2001; Erkmann 
et al., 2005; Farny et al., 2008; Taniguchi and 
Ohno, 2008; Read and Digard, 2010). The 
nuclear export of intron-containing mRNAs 
and intronless mRNAs might be differently 
regulated by signal transduction pathways. 
Histone mRNAs present a matched set of 
RNAs suitable for examining splicing-depen-
dent differences. Although most histone 
mRNAs are intronless, a few are spliced. We 
performed an analysis of nuclear-to-cyto-
plasmic partitioning for the intronless his-
tone mRNAs—H2B, H4, and H3A 
(Figure 6B)—and for the spliced histone mR-
NAs—H1F0, H1FX, and H3F3 (Figure 6C). 
Once again drug inhibition of AKT decreased 
the nuclear-to-cytoplasmic ratio of all histone 
mRNAs, consistent with an increased rate of 
nuclear export. The presence of an intron 
did not change the regulation by AKT. Of 
interest, the inhibition of PI3 kinase increased 
the nuclear retention of spliced histone 
H1FX and H3F3 mRNAs but did not signifi-
cantly affect the nuclear export of spliced 
histone H1F0. The nuclear export of all his-
tone mRNAs was unaffected by rapamycin 
treatment to inhibit mTOR.
Although the drug treatments were 
short, we checked to see whether they were 
able to affect the transcription of the 
mRNAs used in Figure 6A. There were 
some modest drug-specific and transcript-
specific changes in total cellular levels of 
these mRNAs (Supplemental Figure S4), 
but these changes could not account for 
the differences in nuclear-to-cytoplasmic 
ratios.
Overexpression of the mRNA splicing 
factor SRm160 causes the appearance of intron-containing mRNAs 
in the cytoplasm (McCracken et al., 2002). The PI3 kinase/AKT sig-
naling pathway can change the alternative splicing of fibronectin 
mRNA (Blaustein et al., 2005). We wondered, therefore, whether 
the effects on mRNA partitioning seen after AKT inhibition might 
involve increased export of unspliced mRNA. Quantification of 
spliced and unspliced GAPDH (Supplemental Figure S5) showed 
that drug inhibition of AKT inhibition did significantly increase the 
amount of unspliced mRNA in the cytoplasm. The effect was small, 
however, and could not account for the enhanced export of GAPDH 
mRNA. In addition, based on the ΔΔCt values, the ratio of spliced 
to intron-containing RNA in the cytoplasm was, on average, 13, a 
level insignificant relative to the difference in partitioning after AKT 
inhibition (Figure 5A).
mRNAs encoding either endoplasmic reticulum (ER)–targeted or 
mitochondrial proteins have, respectively, a SSCR or mitochondrial 
signal coding region (MSCR) that appropriately targets the protein 
in cells. These RNA elements can be found near the 5′ end of 
the open reading frame of most mRNAs that encode secreted, 
membrane-bound, or mitochondrial-targeted proteins, and they en-
code peptide domains that target the newly translated protein to 
noncoding RNA 7SK was used as a nuclear marker, and the mito-
chondrial-encoded and restricted cytochrome B mRNA was used as 
a cytoplasmic marker. As seen in Figure 5A, there was little contami-
nation of nuclear RNA by cytochrome B mRNA and little contamina-
tion of cytoplasmic RNA by the nuclear-restricted 7SK. Drug treat-
ment of cells to inhibit PI3 kinase, AKT, or mTOR did not affect the 
separation. The quality of the separation of nuclear and cytoplasmic 
material was also assessed by Western blotting for the nuclear pro-
tein RNA polymerase II and the cytoplasmic protein γ-tubulin 
(Figure 5B). There was little cross-contamination of the fractions.
Using these validated methods, we quantified the endogenous 
intron-containing mRNAs for glyceraldehyde 3-phosphate dehydro-
genase (GAPDH), Brahma-related gene 1 (BRG1), and heterogeneous 
RNP (hnRNP) Q in the nucleus and cytoplasm of HeLa cells (Figure 
6A). Drug treatment to inhibit PI3 kinase had no significant effect on 
the nuclear-to-cytoplasmic partitioning of these mRNAs. Inhibition of 
AKT, however, caused a large decrease in the nuclear-to-cytoplasmic 
ratios. This result is consistent with an increased rate of nuclear export 
after AKT inhibition but not PI3 kinase inhibition. Active AKT may be 
increasing the nuclear retention of these mRNAs. mTOR inhibition 
did not significantly alter the nuclear-to-cytoplasmic ratios.
FIGURE 4: Inhibition of PI3 kinase or AKT increases cytoplasmic levels and reduces nuclear 
levels of poly(A) RNA. HeLa cells were treated for 4 h with 20 μM LY294002, 5 μM AKT inhibitor 
VIII, or 100 nM rapamycin before FISH. Cells were fixed for 10 min on ice and then hybridized 
with biotinylated 54-mer oligo(dT). The hybridized probe was detected with Alexa 
488–conjugated streptavidin. Cells were counterstained with 4′,6-diamidino-2-phenylindole to 
identify nuclei. (A) Representative field of the poly(A) distribution in untreated HeLa cells. Scale 
bar, 20 μm. (B) Bar graph of poly(A) in the nucleus or cytoplasm. Values are plotted as the 
percentage of the total cellular poly(A). Statistical analysis of the significance of differences 
between untreated and treated samples is by t test. Means are plotted with SDs. ***p ≤ 0.001.
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the other hand, the first element is an SSCR 
or MSCR, then this mRNA will be exported 
by the alternative pathway (Cenik et al., 
2011).
Because AKT inhibition decreased the 
nuclear and increased the cytoplasmic frac-
tions of the selected mRNAs coding for cy-
toplasmic and nuclear proteins (Figure 6), 
we decided to determine whether this sig-
naling pathway would also regulate the nu-
clear export of mRNAs encoding either ER-
targeted or mitochondrial proteins. For this 
experiment we selected mRNAs without an 
intron at their 5′-UTR and examined the 
mRNA and protein sequences to determine 
their fit to consensus SSCR and MSCR mo-
tifs (Palazzo et al., 2007; Cenik et al., 2011)
The ER-targeted protein mRNAs were 
calreticulin (CALR, NM_004343.3), histo-
compatibility (minor) 13 (HM13, NM_178582), 
and olfactory receptor, family 10, subfamily 
A, member 3 (OR10A3, NM_001003745) 
mRNAs, which have 5, 15, and 19 adenines, 
respectively, in their first 70 nucleotides 
(Figure 7A). At the level of amino acid se-
quence, first 25 residues of CALR and 
OR10A3 are rich in leucine and hydrophobic 
amino acids. On the other hand, the first 25 
residues of HM13 are poor in leucine and 
hydrophobic amino acids (Figure 7). The 
drug inhibition of AKT and mTORC1 had no 
significant effect on the nuclear export of 
these mRNAs (Figure 7A), which suggests 
that AKT specifically regulates the nuclear 
export of only a subset of mRNAs requiring 
the TREX complex. Surprisingly, inhibition of 
PI3 kinase slowed the nuclear export of 
these mRNAs (Figure 7).
The nuclear export of selected nuclear 
mRNAs that encode mitochondrial proteins 
was also analyzed. F1 ATP synthase (F1; 
ATP5B), ferredoxin 1 (FDX1), and fumarate 
hydratase (FH) were chosen because these 
mRNAs have few adenines in the first 70 
nucleotides (5, 2, and 6, respectively) and 
because these proteins are rich in hydro-
phobic amino acids (Figure 7B). A fourth mitochondrial protein mRNA, 
isocitrate dehydrogenase 3 (NAD+; IDH3B), was chosen because it 
has 10 adenines in the first 70 nucleotides. The drug inhibition of PI3 
kinase, AKT, and mTORC1 had no significant effect on the nuclear 
export of IDH3B, FDX1, and FH mRNAs (Figure 7B). The inhibition 
of mTORC1 decreased the nuclear export of ATP5B mRNA (Figure 
7B). This profile of signal transduction effects was very different from 
what was observed for mRNAs lacking both MSCRs and SSCRs 
(Figure 6).
Nuclear and cytoplasmic mRNA levels are at a steady state 
determined by the rates of transcription and RNA processing 
and degradation, as well as of mRNA export to the cytoplasm. 
Measurements of mRNA export that depend on nuclear-to-cyto-
plasmic ratios can be confounded by these additional variables. 
First, we decided to test whether the drug inhibition of PI3 kinase, 
AKT, or mTOR would affect the degradation rates or the 
the ER or mitochondria (Palazzo et al., 2007). These sequences also 
promote nuclear export of these mRNAs by a novel mechanism that 
might be less dependent on the TREX complex for export than most 
mRNAs or even be TREX independent (Palazzo et al., 2007; Cenik 
et al., 2011). For both SSCR- and MSCR-containing mRNAs the first 
69 nucleotides after the start codon tend to be adenine poor, 
whereas at the protein level both sequences are leucine rich, as well 
as rich in hydrophobic amino acids (Palazzo et al., 2007; Cenik et al., 
2011). A comprehensive genome analysis showed that genes en-
coding either ER-targeting or mitochondrial proteins tend to lack 
introns in their 5′ untranslated regions (5′-UTRs) when compared 
with other protein-coding genes (Cenik et al., 2011). From this anal-
ysis a model to explain the alternative export mechanism has been 
proposed (Cenik et al., 2011). If the first element emerging from 
RNA polymerase II is an intron, the mRNA will be exported by a 
splicing-dependent pathway using TREX complex assembly. If, on 
FIGURE 5: The separation of nuclear and cytoplasmic RNA. (A) The fidelity of nuclear and 
cytoplasmic RNA separation was assessed by qRT-PCR quantification of RNAs known to be 
restricted to the nucleus or to the cytoplasm. The small nuclear RNA 7SK was the control for the 
nuclear fraction. Cytochrome B mRNA is a mitochondrially encoded transcript and not present 
in the nucleus, making it a good cytoplasmic RNA marker. Ct values were normalized using 
miniUAA1 mRNA from yeast added as an internal standard to each fraction after the separation 
of nuclei and cytoplasm. There was very little nuclear contamination of cytoplasmic RNA and 
very little cytoplasmic contamination of nuclear RNA. Treatment of cells with 20 μM PI3 kinase 
inhibitor LY294002, 5 μM AKT inhibitor VIII, or 100 nM mTOR inhibitor rapamycin did not affect 
the partitioning of either 7SK RNA or cytochrome B mRNA. Each bar represents the average of 
two independent experiments in which triplicates were analyzed. Error bars represent the SE of 
the mean. ns, not significant. (B) The quality of the nuclear–cytoplasmic fractionation was also 
assessed by Western blotting using the large subunit of RNA polymerase II as a nuclear control 
and γ-tubulin as a cytoplasmic control. The results confirmed that nuclear and cytoplasmic 
material was cleanly separated.
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of RNA polymerase II elongation (Sehgal 
et al., 1976; Bensaude, 2011; Nechaev 
and Adelman, 2011), is rapid. Methods 
using recovery from DRB have been de-
veloped to measure rates of transcription 
and transcriptional elongation (Singh and 
Padgett, 2009).
This method (Singh and Padgett, 2009) 
was used to reversibly block transcription 
in HeLa cells and measure transcription 
rates after a chase to remove DRB. After 
100 μM DRB treatment of HeLa cells for 
7 h, the recovery of pre-mRNA levels was 
measured by qRT-PCR using intron–exon 
primer pairs (Supplemental Figure S7). 
Drug inhibition of PI3 kinase, AKT, and 
mTORC1 had some transcript-specific ef-
fects on transcription rate. These changes 
could not, however, account for the 
changes in nuclear-to-cytoplasmic ratios 
of the mRNAs in our mRNA export assays 
(Figure 6). Taken together, our data sug-
gest that the changes in the nuclear-to-
cytoplasmic ratio of candidate mRNAs af-
ter the drug inhibition AKT were not due 
to decreases in their transcription rates or 
increases in their degradation rates. The 
effects of AKT inhibition on nuclear/cyto-
plasmic partitioning were due to mRNA 
export. AKT inhibition increases the rate 
of mRNA export to the cytoplasm for 
mRNAs that lack an SSCR or MSCR motif.
DISCUSSION
mRNA export has been considered a consti-
tutive process; a transcript that is spliced and 
processed would automatically be sent to 
the cytoplasm. On reflection, it would be sur-
prising if export were the only unregulated 
step in the life cycle of an mRNA. Export to 
the cytoplasm, and not processing, may be 
the rate-limiting step in the delivery of some 
mRNAs to the cytoplasm; nuclear dwell times 
of 1–20 min (histone H4 and β-actin, respec-
tively) after processing have been calculated 
for a few selected mRNA species (Gondran 
et al., 1999). Some mature mRNA molecules 
do not leave the nucleus at all (Weil et al., 
2000).
Regulation of the rate of nuclear export or the extent of retention 
for mRNAs could be an especially important mechanism for modu-
lating translatable, cytoplasmic levels of messages with short half-
lives. RNA half-lives in human cells vary from 10 min for c-myc (Dani 
et al., 1984) to >50 h for β-globin (Volloch and Housman, 1981). The 
mean half-life for 5000 profiled mRNAs in mouse fibroblasts is 9 h 
(Schwanhausser et al., 2011). Global profiling of mRNA turnover 
rates in human HepG2 cells shows that mRNAs for many of the most 
important proteins—for example, 15% of transcription factors—
have half-lives of <2 h (Yang et al., 2003).
The combined use of FRAP with the experimental manipulation 
of signal transduction has great potential for identifying the path-
ways that regulate the assembly of specific macromolecular 
transcription rates of the candidate mRNAs used in the export 
assays of Figure 6. We used actinomycin D at a concentration that 
inhibits RNA polymerases I and II (Trask and Muller, 1988). HeLa 
cells were treated (or not) with actinomycin D (0.5 μg/ml) for 7 h 
to inhibit all transcription. Over the last 3 h, cells were also treated 
with the PI3 kinase, AKT, and mTORC1 inhibitors (Supplemental 
Figure S6). The rate of mRNA degradation was not affected by 
drug inhibition of PI3 kinase, AKT, and mTORC1, suggesting that 
the PI3 kinase/AKT and mTORC1 signaling pathways did not 
affect the degradation of the candidate mRNAs of Figure 6.
Recovery of transcription after actinomycin D inhibition re-
quires hours (Schluederberg et al., 1971), but recovery from 
5,6-dichloro-1-β-ribofuranosyl benzimidazole (DRB), an inhibitor 
FIGURE 6: Inhibition of AKT increases cytoplasmic levels and reduces nuclear levels of 
endogenous mRNAs without changing total cellular levels. Cells were treated with LY294002 
(20 μM), AKT inhibitor VIII (5 μM), and rapamycin (100 nM), or were untreated, for 4 h at 37°C. 
Specific mRNAs were quantified in the nuclear and cytoplasmic fractions by qRT-PCR. Ct values 
were normalized using miniUAA1 mRNA from yeast added as an internal standard to each 
fraction after the separation of nuclei and cytoplasm. (A) Quantitative analysis of intron-
containing mRNAs in the nucleus and cytoplasm: GAPDH, BRG1, and hnRNP Q. (B) Analysis of 
histone mRNAs whose genes lack introns: histones H2B, H4, and H3A. (C) Analysis of spliced 
histone mRNAs. The genes for these transcripts contain introns: histones H1F0, H1FX, and 
H3F3. Each point represents the mean of two independent experiments in which triplicates 
were analyzed. Error bars, SEM. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ns, not significant.
1216 | A. J. C. Quaresma et al. Molecular Biology of the Cell
phosphorylated inhibit bulk poly(A) export 
(Okada et al., 2008). In vitro studies show 
that UAP56 binds to mRNA before recruit-
ing ALY/REF and then NXF1. In our speck-
led-domain photobleaching experiments 
(Figure 1), EGFP-tagged versions of UAP56, 
ALY/REF, and NXF1 had a significant de-
crease in the tightly bound “immobile” 
fraction after either PI3 kinase or AKT inhi-
bition. This suggests that the PI3 kinase/
AKT pathway increases the fraction of mac-
romolecular complexes in which these pro-
teins are tightly bound at speckled domains. 
Rapamycin, which inhibits mTOR but not 
the PI3 kinase pathway, did not have this 
effect, establishing specificity to this 
regulation.
A second complex of proteins assem-
bling on a nuclear mRNA is the EJC 
(Kataoka et al., 2000; Le Hir et al., 2000). 
Three proteins of the EJC core complex 
(Tange et al., 2005)—eIF4A3, Y14, and 
MAGOH—also had a decrease in tight 
binding at speckled domains after PI3 ki-
nase and/or AKT inhibition. MAGOH 
showed a larger decrease in its tightly 
bound immobile fraction after mTOR inhi-
bition. It has been reported that Y14 and 
MAGOH form a stable heterodimer (Ballut 
et al., 2005; Le Hir and Seraphin, 2008). 
However, because the binding kinetics of 
the two proteins, as measured by FRAP, are 
different, we conclude that they either must 
be exchanging within the heterodimer or 
are not always dimerized (Figure 3).
We used FRAP as a screening technique 
to connect mRNA export to specific signal 
transduction pathways. Mechanistically, flu-
orescence recovery in our experiments is 
the result of multiple processes. These in-
clude the steps of equilibrium binding and 
diffusion (Lele et al., 2004; Nickerson, 2009): 
1) the unbinding of bleached molecules, 2) 
the unbinding of still-fluorescent molecules 
outside of the bleach zone, 3) the exchange 
of these two pools of molecules by diffu-
sion, and 4) the binding of fluorescent mol-
ecules in the bleach zone. FRAP recovery for 
an mRNA transcript might also depend on 
the movement of a completed and pro-
cessed mRNA transcript away from the tran-
scription site, with recovery coming from unbleached molecules 
binding to a new mRNA being transcribed (Ben-Ari et al., 2010; 
Brody et al., 2011). For screening purposes we used the complex 
nuclear region around single RNA-splicing speckled domains as the 
photobleach target in each cell. Although the transcription and 
splicing of protein-coding genes are enriched at and around these 
speckled domains (Smith et al., 1999; Shopland et al., 2002), there 
may be complexes of mRNA export proteins present that are not yet 
on mRNA and may have unique binding constants. Reported rates 
of protein diffusion in the nucleus (Kruhlak et al., 2000; Carrero et al., 
2003) are much faster than the recoveries we report here. FRAP was 
complexes. Using this screening approach, we showed that the inhi-
bition of either PI3 kinase or AKT in live cells changes the binding 
affinity of mRNA export–related proteins in macromolecular com-
plexes at mRNA-splicing speckled domains. These domains are 
large enough to serve as practical FRAP targets and are enriched in 
mRNA export factors and transcripts.
One branch of the phosphatidylinositol signal transduction 
pathway, downstream from PI3 kinase, operates through AKT 
(Barnett et al., 2005; Franke, 2008). AKT has been reported to 
phosphorylate the mRNA export linker protein ALY/REF in vitro 
(Okada et al., 2008). Point mutants that cannot be AKT 
FIGURE 7: The AKT signaling pathway does not affect the nuclear export of mRNAs encoding 
either ER-targeted or nuclear-encoded mitochondrial proteins. Cells were treated with LY294002 
(20 μM), AKT inhibitor VIII (5 μM), and rapamycin (100 nM), or were untreated, for 4 h at 37°C. 
Specific mRNAs were quantified in the nuclear and cytoplasmic fractions by qRT-PCR. Ct values 
were normalized using miniUAA1 mRNA from yeast added as an internal standard to each 
fraction after the separation of nuclei and cytoplasm. All mRNAs selected for analysis lacked an 
intron in their 5′ untranslated regions. Each point represents the mean of two independent 
experiments in which triplicates were analyzed. Sequence features that have been linked to the 
ALREX pathway are also presented (Palazzo et al., 2007; Cenik et al., 2011). These are the 
number of adenines in the first 70 nucleotides after the start codon and the number of leucine 
and hydrophobic amino acids coded for in the same region. (A) mRNAs encoding ER-targeted 
proteins were CALR (GO:0006984), OR10A3 (GO:0004984), and HM13 (GO:0004190). 
(B) Nuclear-encoded mRNAs for mitochondrial proteins were F1-ATP synthase (ATP5B; 
GO:0000275), FDX1 (GO:0005506), IDH3B (GO:0005962), and FH (GO:0004333). Error bars, 
SEM. *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ns, not significant.
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pathway that are downstream from PI(4,5)P2 but do not involve PI3 
kinase or AKT. Both branches of the PI pathway downstream from 
PI3 kinase affect mRNA export, and these effects may be opposing.
A growing body of work has localized many enzymes and inositol 
lipid intermediates of the PI pathway to sites in the nuclear interior 
and most often to speckled domains (reviewed in Neri et al., 2002; 
Irvine, 2003; Martelli et al., 2006; Okada and Ye, 2009; Barlow et al., 
2010). These include PI(4,5)P2, the substrate of PI3 kinase (Boronen-
kov et al., 1998; Osborne et al., 2001; Stallings et al., 2005; Bunce 
et al., 2006), and several PI3 kinases (Didichenko and Thelen, 2001; 
Resnick et al., 2005). All three isoforms of AKT are observed in both 
the nucleus and the cytoplasm (Brazil et al., 2004; Martelli et al., 
2006). All share a conserved CRM1-interacting nuclear export sig-
nal, suggesting that they can shuttle between nucleus and cyto-
plasm (Saji et al., 2005). The results we report here do not distin-
guish effects of the nuclear versus the cytoplasmic PI pathway on 
mRNA export factor binding or on bulk nuclear poly(A) export. Still, 
the spatial juxtaposition of mRNA export factors and of the PI signal 
transduction pathway that regulates their binding and function is 
unlikely to be a coincidence.
MATERIALS AND METHODS
Constructs
Standard procedures for cloning fluorescent fusion proteins were as 
previously described (Herbert et al., 2002; Wagner et al., 2003, 
2004; Kota et al., 2008). Point mutations were generated using a 
Stratagene (La Jolla, CA) QuikChange Site-Directed Mutagenesis 
Kit (Kota et al., 2008).
Transfections and treatments
HeLa cells were grown on coverslips and then transfected with plas-
mids using Lipofectamine 2000 (Life Technologies, Paisley, United 
Kingdom) in serum-free medium for 4 h. After 48 h, transfected cells 
were treated for 4 h with drugs inhibiting PI3 kinase, AKT, or mTOR. 
PI3 kinase was inhibited with LY294002 (Cayman Chemical, Ann 
Arbor, MI) at a final concentration of 20 μM (Vlahos et al., 1994). 
mTOR was inhibited with rapamycin (Calbiochem, San Diego, CA) 
at a final concentration of 100 nM (Hosoi et al., 1999). AKT inhibitor 
VIII (Calbiochem) was used to inhibit AKT1, AKT2, and AKT3 at a 
final concentration of 5 μM. mRNA degradation rates were mea-
sured after transcription was inhibited for 7 h using actinomycin D at 
a final concentration of 0.5 μg/ml. Transcription rates were mea-
sured by qRT-PCR using intron–exon primer pairs in cells pretreated 
with DRB at final concentration of 100 μM and then at time intervals 
after removal of DRB.
Western blots
Proteins from HeLa cell lysates were separated by 10% SDS–PAGE 
and transferred to nitrocellulose membranes. Western blots were 
probed with primary antibodies, including rabbit antibodies to 
mTOR and phospho-mTOR serine 2448 (both from Millipore, 
Billerica, MA); rabbit antibodies to AKT and AKT-P threonine 308 
(both from Cell Signaling, Danvers, MA); or mouse monoclonal anti-
body to actin (clone 4; ICN/MP, Solon, OH). Secondary anti-rabbit 
or anti-mouse horseradish peroxidase–conjugated secondary anti-
bodies were from GE Healthcare (Little Chalfont, United Kingdom), 
and the detection system used the SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL).
Fluorescence recovery after photobleaching
FRAP assays were performed at 37°C as previously described 
(Wagner et al., 2004; Kota et al., 2008). Leica Confocal Software 
previously used to explore the complex mechanisms of transcription 
and RNA processing at short reporter genes (Ben-Ari et al., 2010; 
Yunger et al., 2010; Brody et al., 2011). Based on these studies, on 
measured rates of transcription at endogenous genes (Singh and 
Padgett, 2009; Wada et al., 2009), and on other studies of transcrip-
tional dynamics (reviewed in Palangat and Larson, 2012), we expect 
the rates of mRNA elongation, movement away from the bleach 
zone, and recovery by additional transcription to be slow relative to 
the photobleach recovery rates we report here. We conclude that 
the changes we observed in photobleach recovery rates caused by 
PI3 kinase, AKT, and mTOR inhibition were effects on the binding of 
mRNA export complex proteins in complexes at transcripts and 
were not measuring steady-state transcript exchange.
We proceeded with experiments to directly measure the effects 
that the same drugs had on the nuclear export of specific tran-
scripts—first, by a standard assay (Okada et al., 2008; Wickramas-
inghe et al., 2010) that evaluates export by measuring FISH localiza-
tion of poly(A) mRNA in the nucleus and the cytoplasm. Inhibition of 
either PI3 kinase or AKT caused a significant decrease in the nuclear-
to-cytoplasmic ratio of poly(A) RNA without changing total poly(A) 
levels (Figure 4). Simultaneous inhibition of PI3 kinase and AKT 
caused a slightly larger and more significant change. One explana-
tion for these changes is that the PI3 kinase/AKT branch of the PI 
pathway induces the nuclear retention of some poly(A) molecules, 
whereas inhibition of the pathway increases the kinetics of their 
export.
When specific mRNA molecules were quantified in the nucleus 
and cytoplasm after drug treatment, the nuclear-to-cytoplasmic ratio 
of all species was significantly decreased by inhibition of AKT but not 
by inhibition of PI3 kinase or mTOR (Figure 6). This effect was seen for 
a subset of spliced and polyadenylated mRNAs, as well as for mRNAs 
from intronless genes and mRNAs lacking a poly(A) tail. These results 
confirmed the global result obtained by measuring poly(A) after AKT 
inhibition (Figure 4). Decreased transcription combined with de-
creased cytoplasmic turnover for a specific mRNA could theoretically 
contribute to reduced nuclear-to-cytoplasmic ratios without changes 
in total cellular levels. We ruled out this possibility by measuring tran-
scription rates (Supplemental Figure 7) and turnover rates (Supple-
mental Figure 6) for each of the mRNAs of Figure 6 after drug treat-
ments. After AKT inhibition, there were no significant changes in 
mRNA turnover, and the changes in transcription rate were transcript 
specific, variable in direction, and could not account for the altered 
nuclear/cytoplasmic partitioning. We conclude that the export of a 
subset of mRNAs from the nucleus to the cytoplasm is regulated by 
the PI3 kinase/AKT signal transduction pathway.
Not all mRNAs were subject to AKT regulation of nuclear export. 
mRNAs targeted to the endoplasmic reticulum by an SSCR motif or 
to mitochondria by an MSCR did not have altered export after drug 
inhibition of the AKT branch of the PI3 kinase pathway (Figure 7).
The differential effects of PI3 kinase versus AKT on the mRNA 
export of specific mRNAs (Figure 6) might result from the branching 
of the PI pathway downstream of PI3 kinase. Our experiments mea-
sure effects of the AKT branch of the downstream pathway. Muta-
tions in budding yeast that reduce inositol hexakis-phosphate (IP6) 
production in the alternative branch of the PI pathway compromise 
mRNA export to the cytoplasm (York et al., 1999). Mutants in plc1, 
ipk2, or ipk1—all required to produce IP6—cause defects in mRNA 
export. IP6 and the Nup42-binding protein Gle1 cooperate to stimu-
late the ATPase activity of the DExD/H helicase Dbp5 (Alcazar-Roman 
et al., 2006; Weirich et al., 2006). Gle1- and IP6-activated Dbp5 re-
models the mRNP to promote transit across nuclear pores to the 
cytoplasm (Tran et al., 2007). These are effects of the PI signaling 
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RNase-free bovine serum albumin (Invitrogen/Life Technologies, 
Carlsbad, CA). 
Nuclear/cytoplasmic fractionation
Nuclear and cytoplasmic fractions were separated by the protocol 
developed by Lamond and colleagues for proteomic studies 
(Andersen et al., 2002). Briefly, equal number of HeLa cells (5 × 105) 
were plated in 15-cm dishes and after 24 h were treated using 
LY294002 (20 μM), AKT inhibitor VIII (5 μM), or rapamycin (100 nM) 
for 4 h. After treatment and trypsinization, cells were centrifuged at 
1000 rpm for 5 min and rinsed with ice-cold phosphate-buffered 
saline. Cell pellets were gently resuspended in 1 ml of lysis buffer A 
+ VRC (10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM dithiothreitol, 2 mM vanadylri-
boside complex, pH 7.9) and immediately split into two tubes la-
beled Total and CN, respectively, and containing 500 μl each. Cells 
from both tubes were kept on ice for 5 min and broken to release 
their nuclei with a prechilled Dounce homogenizer (20 gentle 
strokes with a tight pestle). Dounced cells from the CN tubes were 
centrifuged at 228 × g for 5 min at 4°C. The supernatant was re-
tained as the cytoplasmic fraction and kept on ice. The nuclear pel-
let was washed once again with buffer A + VRC, centrifuged, resus-
pended in 500 μl of buffer S1 + VRC (250 mM sucrose, 10 mM 
MgCl2, 2 mM vanadylriboside complex), and layered over a 500-μl 
cushion of buffer S3 + VRC (880 mM sucrose, 0.5 mM MgCl2, 2 mM 
vanadylriboside complex). Nuclei were then centrifuged at 2800 × g 
for 10 min at 4°C and resuspended in 500 μl of buffer A + VRC. All 
buffers were made using water pretreated with 0.1% (vol/vol) 
diethylpyrocarbonate.
Quantitative real-time PCR
A 120-pg amount of a synthetic, capped, and poly(A)-containing 
mRNA (miniUAA1; Amrani et al., 2008) was in vitro transcribed, puri-
fied, and added to each tube before TRIzol (Invitrogen) extraction. 
This synthetic mRNA worked as an internal standard or calibrator in 
our qRT-PCR measurement of endogenous mRNAs. Total, cytoplas-
mic, and nuclear RNA fractions—now in the presence of 120 pg of 
the synthetic miniUAA1 mRNA—were isolated using TRIzol reagent, 
digested with DNase I recombinant enzyme (Roche), and purified 
with DNA-free RNA kit (Zymo Research, Irvine, CA). cDNAs were 
then synthesized using random primers (Roche) and reverse tran-
scription SuperScript III (Invitrogen). GoTaq mix (Promega, Madison, 
WI) was used to amplify cDNAs.
All curves were normalized by comparative Ct (2
−∆∆Ct) method 
(Wong and Medrano, 2005). Briefly, Ct values were corrected for the 
mean Ct value of miniUAA1 mRNA as follows: First, raw Ct values of 
GAPDH mRNA (Ct,GAPDH) were corrected using Mean Ct,miniUAA1, 
generating a corrected curve for GAPDH mRNA (Ct,GAPDH,C). Then 
Ct,GAPDH – Mean Ct,miniUAA1 = Ct,GAPDH,C. Because an isolation was 
performed separating cytoplasmic and nuclear fractions, we created 
two corrected curves: N-Ct,GAPDH,C for the nuclear fraction of 
GAPDH mRNA and C-Ct,GAPDH,C for the cytoplasmic fraction of 
GAPDH mRNA. The two curves were corrected by C-Mean Ct,miniUAA1 
and N-Mean Ct,miniUAA1, respectively. Although we added the same 
amount of the synthetic mRNA miniUAA1 (120 pg) in every fraction, 
its Ct values were slightly different, so an additional correction was 
performed using C-Mean Ct,miniUAA1 – N-Mean Ct,miniUAA1.
Eventually two corrected set of data were created: the cytoplas-
mic versus nuclear fold change (C/N), represented by 
2 (C  N- )GAPDH,-  C GAPDH,C− −C Ct t, , , and the miniUAA1-corrected fold 
change, represented by 2 C-Mean   N-  miniUAA1 miniUAA1− − MeanC Ctt ,, , 
which must be as close to 1 as possible. Combining both sets of 
(Leica Microsystems, Exton, PA) was used to measure the intensity 
of fluorescence in the bleached region of interest and in the whole 
nuclear profile at each time point. We analyzed those data using 
Excel spreadsheets (Microsoft, Redmond, WA). Any remaining flu-
orescence in the bleached area after the bleach was normalized to 
zero. To calculate the relative fluorescence intensity (Irel) in the 
bleached area, we used three alternative equations. The first one 
(Phair and Misteli, 2000) used the equation Irel,t = N0It/NtI0. The 
second approach used the equation Irel,t = ItN0/Nt − (IpblN0/Npbl)/
(I0 − IpblN0/Npbl). The third equation is derived from the second 
one by subtracting background fluorescence values measured out-
side of the cell from each fluorescence intensity measurement. For 
all three equations N0 is the total nuclear fluorescence before 
bleaching, Npbl is the total nuclear fluorescence in the first image 
taken after the bleach, Nt is the total nuclear fluorescence at time 
t, I0 is the fluorescence in the bleach zone before the bleach, It is 
the fluorescence in the bleach zone at time t, and Ipbl is the fluores-
cence in the bleach zone in the first image taken after the bleach. 
Recovery curves were drawn using Prism 5 (GraphPad Software, La 
Jolla, CA). The percentage of immobile protein (immobile fraction) 
was determined after normalization of fluorescence in the bleached 
area to 0 in the first postbleach image and 1 in the prebleached 
image, and it was calculated as the percentage difference between 
the relative fluorescence asymptote of the recovery curve and a 
relative recovery of 1, a value that would reflect complete recovery 
without an immobile fraction. Individual time points are presented 
as means, with error bars showing standard errors. The best fit for 
these photobleach recoveries was obtained using an exponential 
association curve: F(t) = Fmax(1 – e−kt). All half-times of recovery 
and immobile fractions were calculated from a best fit to this 
equation.
Multiple cells were examined by FRAP over a 2-h interval for 
each drug treatment in each experiment. The times between 
drug addition and photobleaching are reported as a mean. Three 
independent experiments were done for each EGFP-fusion pro-
tein paired with every drug. The recovery data averaged together 
in one recovery curve were from the same confocal session. Drug-
treated and control cells were always from the same transfection 
and photobleached in the same confocal session. The first two 
sets of independent photobleaching experiments were per-
formed on a Leica SP1 laser scanning confocal microscope (Leica, 
Wetzlar, Germany), and the last set (Figures 1 and 3) was per-
formed on a Leica SP5 AOBS system. Results were independent 
of the system used. The results presented were from the Leica 
SP5 AOBS, using a 40×/numerical aperture 1.3 water immersion 
objective. EGFP fluorescence was photobleached using the 488-
nm line of an argon laser for 200 ms at 20 mW. Nuclear speckled 
domains were spot photobleached. EGFP-NXF1, which was less 
concentrated in speckled domains, was region-of-interest 
photobleached.
Fluorescent in situ hybridization
FISH was performed by a modification of Johnson et al. (1991). A 
54-mer oligo(dT) (Qiagen, Valencia, CA) was biotinylated with a 
Roche kit (Roche, Indianapolis, IN). HeLa cells were fixed in 4% 
paraformaldehyde for 10 min on ice and then permeabilized using 
0.5% Triton X-100 in CSK buffer for 5 min at room temperature. 
After dehydration with ethanol to 70% and then 100%, cells were 
probed overnight the biotinylated oligo(dT) at 37°C in the pres-
ence of 15% formamide. After several washes in SSC buffer (4×, 
2×, and 1×) cells were stained for 3 h (at 37°C) with Alexa 488–con-
jugated streptavidin in a buffer with 4× SSC buffer and 1% of 
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data, we have the cytoplasmic versus nuclear corrected and normal-
ized fold change, q(C/N):
q C C Ct t t(C/N) ( (2 )
)
2(C-   N- ) C-MeanGAPDH,C GAPDH,C miniUA= − − −, , , A1
miniUAA1  N-Mean− Ct,
The following primers were used for the quantitative PCR: mini-
UAA1 forward, 5′-GAGAAAAGTTAAGTCGACGCCC-3′; miniUAA1 
reverse, 5′-GGATCTATCGATTTCAATTC-3′; GAPDH forward, 
5′-GGTGGTCTCCTCTGACTTCAACA-3′; GAPDH reverse, 5′-GTT-
GCTGTAGCCAAATTCGTTGT-3′; BRG1 forward, 5′-AAGGACGAC-
GAGAGCAAGAA-3′; BRG1 reverse, 5′-GGATGAAGACCTC-
GCTGA-3′; hnRNP Q forward, 5′-TGCATTGGCAGTTCTTCAAC-3′; 
hnRNP Q reverse, 5′-TCTGCTACTTTGGTCCCTTG-3′; H2B forward, 
5′-CGCTGTTTTTCCTTTTCGTT-3′; H2B reverse, 5′-CTTAGTCAC-
CGCCTTCTTGG-3′; H4 forward, 5′-AGCTGTCTATCGGGCTC-
CAG-3′; H4 reverse, 5′-CCTTTGCCTAAGCCTTTTCC-3′; H3a for-
ward, 5′-GTTCCGCTGTGCTGTTTTTC-3′; H3a reverse, 5′-GTAGCG-
GTGGGGCTTTTTC-3′; H1F0 forward, 5′-GTGAAACCCAAAG-
CAAAGTCC-3′; H1F0 reverse, 5′-AAATAGGAGACAGGAGG-
GAGTGT-3′; H1FX forward, 5′-CAATCCTCTTGCTACCATGTCC-3′; 
H1FX reverse, 5′-GCTATTCTTCCTCTTCTTAGATGGG-3′; H3F3 for-
ward, 5′-TGCGGAGACGTAAAGCATT-3′; H3F3 reverse, 5′-CCGCT-
GAAACTTGTTCACTG-3′; CALR forward, 5′-CTTGGATCCACCCA-
GAAATTG-3′; CALR reverse, 5′-CCTCAGCGTATGCCTCATCG-3′; 
HM13 forward, 5′-CATCAACCTCCTGCTGTCCATG-3′; HM13 re-
verse, 5′-GTACTGGTTCCCGAGAAAGCTG-3′; OR10A3 forward, 
5′-GGAGCGATGGCTTATGACCG-3′; OR10A3 reverse, 5′-CAAGT-
GGTCTGCACAGTAGCC-3′; F1-ATP synthase forward, 5′-TGTCG-
GCTACGGCCTCGGAT-3′; F1-ATP synthase reverse, 5′-GGGTCG-
GCGGAGCAACAGAG; FDX1 forward, 5′-CAGACAGATCACGGT-
TGGGC-3′; FDX1 reverse, 5′-GGAGGTCTTGCCCACATCAATG-3′; 
IDH3B forward, 5′-GAGCAGGTGCTGAGTTCCATG-3′; IDH3B 
reverse, 5′-GTCCAACTTACGCCTCAGCC-3′ ; FH forward, 5′-GCTC-
GAATGGCAAGCCAAAATTC-3′; FH reverse, 5′-CATGCGTTCTGT-
CACACCTCC-3′; GAPDH (exon 1–intron 2) forward, 5′- GGAAGGT-
GAAGGTCGGAGTCAAC-3′; GAPDH (exon 1–intron 2) reverse, 
5′-GCTCTCCTTGCGGGGAACAGCTAC-3′; BRG1 (exon 1–intron 1) 
forward, 5′-GCTTCTTTGTTTCGTGAAGAGAAG-3′; BRG1 (exon 
1–intron 1) reverse, 5′-CGGCTCCATTCAAACCGCCCTC-3′; hnRNP 
Q (intron 1–exon 2) forward, 5′-CTTCAGTACCATTTCCATTAAC-3′; 
hnRNP Q (intron 1–exon 2) reverse, 5′-GGTATAGGCTAGCTGGTG-
TAG-3′; H3F3A (exon 1–intron 2) forward, 5′-CATAATTTCCAGATTT-
GGGGAGG-3 ′; H3F3A (exon 1–intron 2) reverse, 5′-GATTTGC-
GGGCAGTCTGCTTTG-3′.
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